Mizagliflozin (KWA 0711)

InformationMizagliflozin (KWA 0711) Mizagliflozin (KWA 0711) is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.Targetshuman SGLT1 (Cell-free assay) 27 nM(Ki)In vitroMizagliflozin\'s inhibitory activity against SGLTs is evaluated by an in vitro assay of cells transiently expressing SGLTs. Mizagliflozin potently inhibits human SGLT1 in a highly selective manner..In vivoThe oral administration of Mizagliflozin increased fecal wet weight in a dog model of loperamide-induced constipation and a rat model of low-fiber-diet-induced constipation..Cell Research(from reference)Cell lines：COS-7 cells Concentrations：0-1 μM, 0-30 μM Incubation Time：1 h

Specifictaions: Moligand™, ≥98%

MDL Number: C28H44N4O8

Molecular Formula: 564.67

PubChem CID: 10460535

Isomeric SMILES: CC1=C(C=CC(=C1)OCCCNCC(C)(C)C(=O)N)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(C)C